Hima Venkata Vangapandu

Hima Venkata Vangapandu

Auto-generated profile, based on publicly available information

Hima Venkata Vangapandu

Houston, TX

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 September 2013 in The FASEB Journal
Verified
Journal Article
Open access
PDF file
TMTANNOUR LOUET Mounia
TANNOUR LOUET Mounia
SLShaye K. Lewis
Shaye K. Lewis
JLJean-Francois Louet
Jean-Francois Louet
JSJulie Stewart
Julie Stewart
JAJosephine B. Addai
Josephine B. Addai
DLDolores J. Lamb
Dolores J. Lamb
A major limitation of exogenous vitamin D 3 administration for the treatment of prostate cancer is the marginal, if any, clinical efficacy. We dissected the basis for the resistance to the vitamin D 3 antitumor properties and specifically examined the effect of its major catabolic enzyme, CYP24A1, in prostate cancer. Local CYP24A1 expression levels and the effect of selective modulation were analyzed using tissue microarrays from needle core biopsy specimens and xenograft‐bearing mouse models. CYP24A1 mRNA was elevated in malignant human prostate tissues compared to benign lesions. High CYP24A1 protein levels were seen in poorly differentiated and highly advanced stages of prostate cancer and correlated with parallel increase in the tumor proliferation rate. The use of CYP24A1 RNAi enhanced the cytostatic effects of vitamin D 3 in human prostate cancer cells. Remarkably, subcutaneous and orthotopic xenografts of prostate cancer cells harboring CYP24A1 shRNA resulted in a drastic reduction in tumor volume when mice were subjected to vitamin D 3 supplementation. CYP24A1 may be a predictive marker of vitamin D 3 clinical efficacy in patients with advanced prostate cancer. For those with up‐regulated CYP24A1, combination therapy with RNAi targeting CYP24A1 could be considered to improve clinical responsiveness to vitamin D 3 .—Tannour‐Louet, M., Lewis, S. K., Louet, J.‐F., Stewart, J., Addai, J. B., Sahin, A., Vangapandu, H. V., Lewis, A. L., Dittmar, K., Pautler, R. G., Zhang, L., Smith, R. G., Lamb, D. J. Increased expression of CYP24A1 correlates with advanced stages of prostate cancer and can cause resistance to vitamin D 3 ‐based therapies. FASEB J . 28, 364–372 (2014). www.fasebj.org

14 March 2014 in Journal of Hematology & Oncology
Verified
Journal Article
Open access
PDF file
CSChristine Stellrecht
Christine Stellrecht
HVHima V Vangapandu
Hima V Vangapandu
XLXiao-Feng Le
Xiao-Feng Le
WMWeiqun Mao
Weiqun Mao
SSShujun Shentu
Shujun Shentu
8-chloro-adenosine (8-Cl-Ado) is a unique ribonucleoside analog which is currently in a phase I clinical trial for hematological malignancies. Previously, we demonstrated in breast cancer cells that a 3-day treatment with 10 μM 8-Cl-Ado causes a 90% loss of clonogenic survival. In contrast, there was only a modest induction of apoptosis under these conditions, suggesting an alternative mechanism for the tumoricidal activity of 8-Cl-Ado. Cellular metabolism, AMP-activated protein kinase (AMPK) and mammalian target of rapamycin (mTOR) pathway signaling, as well as autophagy induction was evaluated in breast cancer cell lines treated with 8-Cl-Ado. The effects of knocking down essential autophagy factors with small interfering RNA on 8-Cl-Ado-inhibited cell survival was assessed in breast cancer cells by examining apoptosis induction and clonogenic survival. In vivo efficacy of 8-Cl-Ado was measured in two breast cancer orthotopic model systems. We demonstrate that in breast cancer cell lines, the metabolism of 8-Cl-Ado results in depletion of endogenous ATP that subsequently induces the phosphorylation and activation of the energy sensor, AMPK. This was associated with an attenuation of mTOR signaling and an induction of the phosphorylation of the autophagy factor, Unc51-like kinase 1 on Ser555. 8-Cl-Ado-mediated induction of autophagy was evident by increased aggregates of microtubule-associated protein 1 light chain 3B (LC3B) which was associated with its conversion to its lipidated form, LC3B-II, p62 degradative flux, and increased formation of acidic vesicular organelles. Additionally, transfection of MCF-7 cells with siRNA to ATG7 or beclin 1 provided partial protection of the cells to 8-Cl-Ado cytotoxicity as measured by clonogenicity. In vivo, 8-Cl-Ado inhibited growth of both MCF-7 and BT-474 xenograft tumors. Moreover, in 9 of 22 BT-474 tumors treated with 100 mg/kg/day 3 times a week, there was an absence of macroscopically detectable tumor after 3 weeks of treatment. Our data demonstrates that 8-Cl-Ado treatment activates the AMPK pathway leading to autophagy induction of in breast cancer cells, eliciting, in part, its tumoricidal effects. Additionally, 8-Cl-Ado effectively inhibited in vivo tumor growth in mice. Based on this biological activity, we are planning to test 8-Cl-Ado in the clinic for patients with breast cancer.

7 March 2013 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ASAustin Y. Shull
Austin Y. Shull
MCMegan L. Clendenning
Megan L. Clendenning
SGSampa Ghoshal-Gupta
Sampa Ghoshal-Gupta
CFChristopher L. Farrell
Christopher L. Farrell
HVHima V. Vangapandu
Hima V. Vangapandu
PBPhillip J. Buckhaults
Phillip J. Buckhaults
The Cub and Sushi Multiple Domains 1 (CSMD1) gene, located on the short arm of chromosome 8, codes for a type I transmembrane protein whose function is currently unknown. CSMD1 expression is frequently lost in many epithelial cancers. Our goal was to characterize the relationships between CSMD1 somatic mutations, allele imbalance, DNA methylation, and the clinical characteristics in colorectal cancer patients. We sequenced the CSMD1 coding regions in 54 colorectal tumors using the 454FLX pyrosequencing platform to interrogate 72 amplicons covering the entire coding sequence. We used heterozygous SNP allele ratios at multiple CSMD1 loci to determine allelic balance and infer loss of heterozygosity. Finally, we performed methylation-specific PCR on 76 colorectal tumors to determine DNA methylation status for CSMD1 and known methylation targets ALX4, RUNX3, NEUROG1, and CDKN2A. Using 454FLX sequencing and confirming with Sanger sequencing, 16 CSMD1 somatic mutations were identified in 6 of the 54 colorectal tumors (11%). The nonsynonymous to synonymous mutation ratio of the 16 somatic mutations was 15∶1, a ratio significantly higher than the expected 2∶1 ratio (p = 0.014). This ratio indicates a presence of positive selection for mutations in the CSMD1 protein sequence. CSMD1 allelic imbalance was present in 19 of 37 informative cases (56%). Patients with allelic imbalance and CSMD1 mutations were significantly younger (average age, 41 years) than those without somatic mutations (average age, 68 years). The majority of tumors were methylated at one or more CpG loci within the CSMD1 coding sequence, and CSMD1 methylation significantly correlated with two known methylation targets ALX4 and RUNX3. C:G>T:A substitutions were significantly overrepresented (47%), suggesting extensive cytosine methylation predisposing to somatic mutations. Deep amplicon sequencing and methylation-specific PCR reveal that CSMD1 alterations can correlate with earlier clinical presentation in colorectal tumors, thus further implicating CSMD1 as a tumor suppressor gene.

1 January 2015 in Fertility and Sterility
Verified
Journal Article
Closed access
CJCarolina J. Jorgez
Carolina J. Jorgez
NWNathan Wilken
Nathan Wilken
JAJosephine B. Addai
Josephine B. Addai
JNJustin Newberg
Justin Newberg
HVHima V. Vangapandu
Hima V. Vangapandu
DLDolores J. Lamb
Dolores J. Lamb

9 September 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
CJCarolina J. Jorgez
Carolina J. Jorgez
JRJill A. Rosenfeld
Jill A. Rosenfeld
NWNathan R. Wilken
Nathan R. Wilken
HVHima V. Vangapandu
Hima V. Vangapandu
ASAysegul Sahin
Aysegul Sahin
DLDolores J. Lamb
Dolores J. Lamb
Normal development of the genitourinary (GU) tract is a complex process that frequently goes awry. In male children the most frequent congenital GU anomalies are cryptorchidism (1–4%), hypospadias (1%) and micropenis (0.35%). Bladder exstrophy and epispadias complex (BEEC) (1∶47000) occurs less frequently but significantly impacts patients' lives. Array comparative genomic hybridization (aCGH) identified seven individuals with overlapping deletions in the 2p15 region (66.0 kb-5.6 Mb). Six of these patients have GU defects, while the remaining patient has no GU defect. These deletions encompass the transcription factor OTX1. Subjects 2–7 had large de novo CNVs (2.39–6.31 Mb) and exhibited features similar to those associated with the 2p15p16.1 and 2p15p14 microdeletion syndromes, including developmental delay, short stature, and variable GU defects. Subject-1 with BEEC had the smallest deletion (66 kb), which deleted only one copy of OTX1. Otx1-null mice have seizures, prepubescent transient growth retardation and gonadal defects. Two subjects have short stature, two have seizures, and six have GU defects, mainly affecting the external genitalia. The presence of GU defects in six patients in our cohort and eight of thirteen patients reported with deletions within 2p14p16.1 (two with deletion of OTX1) suggest that genes in 2p15 are important for GU development. Genitalia defects in these patients could result from the effect of OTX1 on pituitary hormone secretion or on the regulation of SHH signaling, which is crucial for development of the bladder and genitalia.

30 April 2012 in Journal of Urology
Verified
Journal Article
Closed access
PDF file
CJCarolina Jorgez
Carolina Jorgez
SBShelly Bian
Shelly Bian
VVVenkata Vangapandu
Venkata Vangapandu
ASAysegul Sahin
Aysegul Sahin
DLDolores Lamb
Dolores Lamb